XENE is one of three companies open in full. Every company in our coverage universe has a Thesis like this one.
Sign up freeXenon Pharmaceuticals is developing azetukalner, an oral potassium-channel opener, for epilepsy and depression; it is not approved and has been submitted to FDA for focal seizures.
Xenon's case rests on azetukalner in focal onset seizures. In Phase 3 X-TOLE2 the 25 mg dose cut seizures 53.2% versus 10.4% on placebo, and Xenon submitted the NDA on September 17, 2026. The same day it paused new enrollment in its depression and bipolar trials after neuropsychiatric adverse events; epilepsy studies continue. X-NOVA2 closed at about 360 patients, with depression data in the first quarter of 2027. Cash of $1.25 billion is expected to last into 2029.
Thesis checklist
1 risk needs attention
Xenon submitted the NDA on September 17, 2026. In X-TOLE2, 54.8% of 25 mg patients had at least a 50% seizure reduction versus 20.8% on placebo; dizziness was the most common side effect.
What would weaken it
Xenon paused new enrollment in its MDD and bipolar trials after neuropsychiatric adverse events, with its safety board, and is evaluating dose changes. Enrolled patients continue.
What would weaken it
Enrollment in X-NOVA2 closed at about 360 patients after the pause; Xenon will complete dosing and unblind, with topline data in the first quarter of 2027.
What would weaken it
Cash, equivalents and marketable securities were $1,245.1 million at June 30, and Xenon expects to fund operations into 2029.
What would weaken it
Next decision point
Tests: FDA approves azetukalner for focal seizures
Does FDA accept the NDA and review it without new psychiatric safety demands?
Focal epilepsy is the first market and the basis of Xenon's value.
| Outcome | Evidence to look for | Checklist effect |
|---|---|---|
| Strong | Acceptance with a standard review and no new safety requests. | Checklist effect:Keeps approval on track. |
| Inconclusive | Acceptance with extra safety information requests. | Checklist effect:Adds review risk. |
| Weak | Refusal to file or a demand for new studies. | Checklist effect:Delays the first launch. |
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Xenon submitted the azetukalner NDA for focal onset seizures and paused new enrollment in its depression and bipolar trials after neuropsychiatric adverse events; epilepsy studies continue.
The epilepsy filing is in, but the neuropsychiatric events behind the psychiatry pause raise safety questions for the drug that are not yet explained.
Source ↗X-TOLE2 met its Phase 3 primary endpoint at both doses: monthly FOS frequency fell 53.2% at 25 mg and 34.5% at 15 mg versus 10.4% placebo.
Both doses succeeded, while the stronger 25 mg placebo-adjusted effect versus Phase 2b reinforces the higher-dose efficacy signal.
Source ↗Adjunctive drugs such as Xcopri, Fycompa and Briviact are approved for focal seizures, and most patients take several. Praxis's sodium-channel drug vormatrigine missed in POWER1, and Ovid's OV329 is in Phase 2. Azetukalner opens Kv7 potassium channels; in X-TOLE2, 25 mg cut seizures 53.2% versus 10.4% on placebo, with dizziness as the most common side effect. Biohaven's Kv7 opener opakalim is in Phase 2/3 in epilepsy.
| Product | Target | Administration | Status |
|---|---|---|---|
Company product azetukalner Xenon | Kv7 potassium channel | oral | Filed |
| Approved | |||
Briviact brivaracetam · UCB | SV2A | oral · twice daily | Approved |
Fycompa perampanel · Catalyst | AMPA glutamate receptor | oral · once daily at bedtime | Approved |
Xcopri cenobamate · SK Life Science | sodium current modulator / GABA-A positive modulator | oral · once daily | Approved |
| In development | |||
vormatriginedirect Praxis Precision Medicines | hyperexcitable state of brain sodium channels (NaV) | — | Phase 2/3 (POWER1 missed; restarting Q4 2026) |
Ovid | GABA-AT (4-aminobutyrate aminotransferase) | — | Phase 2 |
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.